CSL Behring announced results of a Phase 3b study that showed that a balanced, human 4-factor prothrombin complex concentrate (PCC) is as effective as the current standard of treatment in stopping ...
A "genetic thrombophilia," or an inherited predisposition to develop blood clots, affects both you and your family. Genetic changes (also called mutations) in clotting factors, like factor V and ...
PARAMUS, N.J., July 26, 2023 – Octapharma USA today announced that Balfaxar ® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex ®) has received U.S. Food and Drug ...
Thirteen patients with liver disease and an abnormal prothrombin time refractory to vitamin K therapy were studied (Tables 1 and 2). None of the patients were actively bleeding, and none had received ...
PARAMUS, N.J., April 2, 2025 /PRNewswire/ -- Octapharma USA announced the Journal of the American Medical Association (JAMA) has published results from a Phase III clinical trial, which observed ...
Background: ABO blood type locus has been reported to be an important genetic determinant of venous and arterial thrombosis in genome-wide association studies. We tested the hypothesis that ABO blood ...
PLEASANTON, Calif., Feb. 13, 2018 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA clearance for the cobas® Factor II and Factor V Test for use on the cobas® ...
Researchers used x-ray crystallography to publish the first image of prothrombin. The protein’s flexible structure is key to the development of blood-clotting. Blood-clotting has long ensured our ...
Agena Bioscience, Inc., a life sciences and clinical diagnostics company, which recently acquired the bioscience business of Sequenom, Inc., was notified by Sequenom, Inc. that it received premarket ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback